Chandrakant Lahariya | Flu-COVID Combo Vaccines: An Idea Whose Time Has Not Yet Arrived

Six years after the world was turned upside down by the Covid-19 pandemic, vaccine manufacturers are once again turning to innovation. Global pharmaceutical giants such as Moderna, Pfizer and Novavax and several Indian firms are advancing Phase 3 trials of flu-Covid combination vaccines. From a product design perspective, it is elegant. However, from a business and political perspective, the situation is much more complex.

The real question is no longer whether such a vaccine can be developed. It’s whether it makes commercial, epidemiological and operational sense in today’s context. In 2020 and 2021, Covid-19 was an acute global emergency and influenza was a predictable seasonal burden. Combining the two seemed fruitful. But in the meantime the world has changed a lot. Covid-19 has become largely endemic and the need for routine boosters for the general population remains unclear.

Even in high-income markets, updated Covid promoters have struggled to maintain demand. In India and many middle-income countries, Covid vaccination has largely detracted from public health priorities. In contrast, influenza maintains a steady, if modest, annual demand, especially among older adults, healthcare workers, and those with comorbidities. This difference in demand is not accidental; is central to the commercial viability of any combination product.

Flu vaccines benefit from the institutional trust they have built over decades. Their safety, effectiveness, and regulatory pathways are well understood. Although Covid-19 vaccines are a scientific breakthrough, they have faced misinformation, politicization and evolving public narratives. Reputation risks are shared in the combination product. If some segments of the population remain hesitant about Covid boosters, linking them to flu vaccines could also undermine confidence in the latter. In a country like India, where vaccine coverage for adults is already limited, this is a significant downside risk. Combining a stable product with a product facing uncertain demand can increase rather than reduce volatility.

Operational challenges add another layer of complexity. The combination vaccine is not just two antigens in one vial. It requires careful calibration of immunogenicity, dose optimization, adjuvant compatibility and stability. Manufacturing processes are becoming more complex and regulatory scrutiny is intensifying. Authorities need to evaluate not only each component but also their interaction and the combined immune response.

Both flu and Covid vaccines require periodic updates. Influenza follows a relatively predictable seasonal pattern driven by global surveillance. But SARS-CoV-2 continues to evolve unpredictably. Synchronizing update cycles for a combination vaccine could complicate manufacturing timelines, delay regulatory approvals, and increase postmarketing surveillance requirements. For manufacturers, this means higher costs, longer lead times and uncertain returns.

There is also a mismatch in target populations. The flu vaccine is recommended for children, pregnant women, the elderly and people with comorbidities. Covid support policies have become more selective, largely focused on older adults and high-risk groups. Covid vaccination for young children has never been a broad priority in India. Therefore, a universal flu-Covid combination would not be fully compatible with current recommendations. If a child needs protection against the flu but does not need the Covid vaccine, the combination becomes counterproductive. Separate formulations will still be required, undermining the simplicity that combination vaccines are intended to achieve.

Market realities in India further complicate the picture. The seasonal flu vaccine market, although small, has remained relatively stable at around 150-300 billion rupees annually, driven by urban private healthcare and institutional vaccination programmes. On the other hand, demand for Covid supplements has decreased sharply. A combination product will attempt to combine a small but predictable market with a weak and uncertain market; This is hardly a compelling business proposition.

India’s problem lies not only in product innovation but also in system readiness. Vaccination of adults remains underdeveloped compared to the Universal Immunization Program for children. Coverage is low not only for flu or Covid, but also for pneumococcal, hepatitis B and HPV vaccines. The combination vaccine does little to correct these structural deficiencies.

None of this argues against innovation. Continued investment in vaccine platforms such as mRNA, viral vectors and protein subunits is strategically important. Even if the Flu-Covid combination is not widely adopted, underlying capabilities remain valuable for future-proofing.

There is also a global dimension. Combination vaccines may find a place in high-income countries where aging populations have become accustomed to annual boosters and health systems can absorb higher costs. Convenience and fewer clinic visits offer tangible benefits. But in middle-income countries, where health budgets are tight and decisions are closely tied to perceived disease burden, the value proposition is less clear.

We also need to sort out our priorities. Public health gains often result from incremental improvements in coverage and access rather than technological packages alone. There is no rush to bring the combination product to market; Instead, it is necessary to strengthen adults’ vaccine ecosystems and rebuild trust in vaccines throughout life. The flu vaccine deserves continued and independent promotion.

The Flu-Covid combination vaccine is an interesting idea; scientifically sound and commercially creative. But in the current context, there is a risk of solving yesterday’s problem while complicating today’s realities. The real question for policymakers, investors and industry leaders is not whether these vaccines can be combined, but whether doing so increases coverage, confidence and cost-effectiveness. The idea may find its moment in the future, but that moment has not yet come.

Dr Chandrakant Lahariya is a senior consultant cardio-metabolic physician and an expert on health policy and vaccines.